EMERYVILLE, Calif.--(BUSINESS WIRE)--Jan. 23, 2006--Chiron Corporation (Nasdaq:CHIR) today announced that the European Commission has granted marketing approval for CUBICIN(R) (daptomycin), a first-in-class IV antibiotic. The marketing approval was granted in the 25 member states of the European Union, Iceland, Liechtenstein and Norway. Under the approval, CUBICIN is indicated for the treatment of complicated skin and soft-tissue infections (cSSTI) caused by Gram-positive bacteria. CUBICIN is expected to become available in the United Kingdom and the Netherlands within the next few weeks, followed by additional European countries, in accordance with local legal regulations.
